Try our beta test site

Placement of Covered Stents to Treat Hemodialysis Access Stenoses in the Cephalic Arch and Central Veins

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2011 by American Access Care.
Recruitment status was:  Recruiting
Information provided by:
American Access Care Identifier:
First received: December 1, 2010
Last updated: January 6, 2011
Last verified: January 2011

Balloon angioplasty is used to open up a narrowing that forms in hemodialysis fistula. Two areas of particular problems are the terminal portion of the cephalic vein near the shoulder and the central veins in the chest. Although angioplasty is standard of care the treated narrowed segments of vein mostly renarrow within 3 months requiring retreatment to keep your dialysis access functional. Recently there has been introduction of a new technology called a covered stent graft. Initial studies suggest that placing this device across the area of narrowing leads to dialysis access staying open longer and needing less angioplasty treatments.

This study is designed to compare angioplasty (standard of care) versus using a covered stent graft. The investigators will then look at the dialysis records and future fistulograms to see if there is decreased flow through the fistula at 3, 6 and 12 months after the initial procedure.

Condition Intervention
Other: PTA alone without use of the GORE VIABAHN
Device: GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Placement of Covered Stents to Treat Hemodialysis Access Stenoses in the Cephalic Arch and Central Veins

Resource links provided by NLM:

Further study details as provided by American Access Care:

Primary Outcome Measures:
  • Primary patency at 3, 6, and 12 months [ Time Frame: 1 year ]
    Target lesion primary patency at 3, 6, and 12 months

Secondary Outcome Measures:
  • Secondary patency at 3, 6, and 12 months [ Time Frame: 1 year ]
    Target lesion secondary patency at 3, 6, and 12 months, access circuit primary and secondary patency at 3, 6, and 12 months, anatomic, clinical, and procedural success. Adverse events through 1 month

Estimated Enrollment: 140
Study Start Date: October 2010
Estimated Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Percutaneous Transluminal Angioplasty (PTA) alone
Intervention: Procedure: PTA alone without use of the GORE VIABAHN
Other: PTA alone without use of the GORE VIABAHN
PTA alone with no stent used
Experimental: PTA with covered stent
GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
Device: GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
Covered stent produced by GORE VIABAHN
Other Name: Covered stent


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Hemodialysis patient with a mature forearm or upper arm access that was created > 2 months before enrollment in study.
  2. The patient is ≥ 18 years of age.
  3. The patient has a reasonable expectation of remaining on hemodialysis for 12 months.
  4. The patient or his/her legal guardian understands the study and is willing and able to comply with follow-up requirements.
  5. The patient or his/her legal guardian is willing to provide informed consent.
  6. The patient has lesions that meet the angiographic inclusion / exclusion criteria and induce clinical, hemodynamic or functional abnormality.

Exclusion Criteria:

  1. The patient has a known or suspected systemic infection.
  2. The patient has a known or suspected infection of the hemodialysis access and / or bacteremia.
  3. The patient is currently taking maintenance immunosuppressant medication such as rapamycin, mycophenolate or mycophenolic acid, prednisone (>10 mg per day), cyclosporine, tacrolimus, or cyclophosphamide.
  4. The patient has known bleeding disorder (e.g., hemophilia or von Willebrand's disease).
  5. The patient has known sensitivity to heparin.
  6. The patient is scheduled for a live donor kidney transplant.
  7. The patient is enrolled in another investigational study or another access maintenance trial
  8. The patient has comorbid conditions that may limit their ability to comply with the follow-up requirements
  9. Life expectancy is ≤ 24 months.
  10. The patient has an untreatable allergy to radiographic contrast material.
  11. The patient is pregnant.
  12. In the opinion of the operating physician, the patient's hemodialysis access circuit is unsuitable for endovascular treatment.
  13. The patient's access is planned to be abandoned within 1 year.
  14. The patient has indwelling catheters (dialysis, pacemakers, ports).
  15. The patient has a central vein stent that would lead to jailing of the internal jugular vein.
  16. The patient experiences angioplasty-induced venous rupture.
  17. The patient has a flow limiting dissection after angioplasty.
  18. The patient's hemodialysis access is thrombosed.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01271881

United States, New York
American Access Care of Bronx
Bronx, New York, United States, 10461
American Access Care of Queens
Flushing, New York, United States, 11366
Access Care Physicians of New York
White Plains, New York, United States, 10601
Sponsors and Collaborators
American Access Care
Principal Investigator: Abigail Falk, Dr. American Access Care Physician
Study Chair: Claudio Cantu, RPA American Access Care Center Operations Manager
  More Information

Additional Information:

Responsible Party: Dr. Abigail Falk, American Acess Care Identifier: NCT01271881     History of Changes
Other Study ID Numbers: GORE-01 
Study First Received: December 1, 2010
Last Updated: January 6, 2011

Keywords provided by American Access Care:
Adult patients who are currently receiving hemodialysis treatment via an AV vascular graft or fistula located in the upper extremity

Additional relevant MeSH terms:
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action processed this record on February 20, 2017